AstraZeneca Pharma India Limited (BOM:506820)
9,211.50
+22.60 (0.25%)
At close: Dec 5, 2025
AstraZeneca Pharma India Revenue
AstraZeneca Pharma India had revenue of 5.59B INR in the quarter ending September 30, 2025, with 37.03% growth. This brings the company's revenue in the last twelve months to 20.06B, up 35.14% year-over-year. In the fiscal year ending March 31, 2025, AstraZeneca Pharma India had annual revenue of 17.16B with 32.48% growth.
Revenue (ttm)
20.06B
Revenue Growth
+35.14%
P/S Ratio
11.48
Revenue / Employee
33.44M
Employees
802
Market Cap
230.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 17.16B | 4.21B | 32.48% |
| Mar 31, 2024 | 12.96B | 2.93B | 29.17% |
| Mar 31, 2023 | 10.03B | 1.97B | 24.50% |
| Mar 31, 2022 | 8.06B | -79.60M | -0.98% |
| Mar 31, 2021 | 8.14B | -182.50M | -2.19% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 10.00T |
| Life Insurance Corporation of India | 9.14T |
| State Bank of India | 3.57T |
| Larsen & Toubro | 2.76T |
| HDFC Bank | 2.68T |
| Tata Consultancy Services | 2.58T |
| Bharti Airtel | 1.95T |
| ICICI Bank | 1.91T |
AstraZeneca Pharma India News
- 18 days ago - AstraZeneca Pharma India jumps 3% after teaming up with Sun Pharma to boost access to Hyperkalaemia treatment in India - Business Upturn
- 19 days ago - AstraZeneca and Sun Pharma partner to boost access to Hyperkalaemia treatment in India - Business Upturn
- 7 weeks ago - AstraZeneca Pharma India to launch hyperkalemia treatment ‘Lokelma’ in November 2025 - Business Upturn
- 2 months ago - AstraZeneca Pharma India secures CDSCO approval for additional indication of Enhertu - Business Upturn
- 3 months ago - AstraZeneca Pharma receives Rs 60.49 crore NPPA show cause notice over Symbicort pricing - Business Upturn
- 4 months ago - AstraZeneca Pharma shares rise over 2% after company swings back to profit in Q1 - Business Upturn
- 4 months ago - AstraZeneca Pharma Q1 Results: Revenue up 36% YoY to Rs 526 crore, Net Profit at Rs 55 crore - Business Upturn
- 5 months ago - AstraZeneca Pharma gets CDSCO approval to import and sell Imfinzi for additional indication - Business Upturn